GLP-1 vs GIP vs Glucagon Agonism

In the past five years, three letters have rewritten how researchers and clinicians think about metabolic disease: GLP-1, GIP, and glucagon. These aren't drugs — they're receptors, each engaged by an endogenous hormone that helps regulate glucose, appetite, and energy expenditure. The drugs and research peptides built around them have produced some of the most studied metabolic compounds of the decade, from semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro, Zepbound) to investigational compounds like Retatrutide.

For Canadian research labs working with these compounds — or anyone trying to understand why GLP-1/GIP/glucagon triple agonists matter — the pharmacology behind them is worth understanding properly. This post explains how each receptor works, why combining them produces effects that single-receptor compounds can't, and what the progression from single to dual to triple agonist means for current research. The peptides discussed here sit at the center of our Weight Management Collection.

The short version: GLP-1 reduces appetite and improves glucose handling. GIP amplifies insulin release and modulates fat tissue. Glucagon, counterintuitively, increases energy expenditure when activated alongside GLP-1. Combining all three produces metabolic effects no single mechanism can achieve alone. The long version is more interesting.

At a Glance: GLP-1 vs GIP vs Glucagon Receptor Pharmacology

Receptor	Native Hormone	Primary Tissue Effects	Net Metabolic Result
GLP-1	Glucagon-like peptide-1	Pancreas, brain, gut	Insulin release, appetite reduction, slowed gastric emptying
GIP	Glucose-dependent insulinotropic polypeptide	Pancreas, adipose tissue, brain	Insulin amplification, adipose modulation, complex satiety effects
Glucagon (GcgR)	Glucagon	Liver, adipose tissue	Hepatic glucose output, lipolysis, energy expenditure

Single-agonist drugs target one of these. Dual agonists target two. Triple agonists target all three. The research peptide that defines the triple-agonist class is currently retatrutide.

What Are Incretins? The Biological Foundation

Before getting into individual receptors, it helps to understand what GLP-1 and GIP have in common. Both belong to a hormone class called incretins — gut hormones released in response to food intake that signal the pancreas to release insulin. The discovery of incretins solved a long-standing puzzle in endocrinology: oral glucose triggers a much larger insulin response than intravenous glucose at the same blood concentration. The gut, it turned out, was sending hormonal signals to the pancreas that "anticipated" incoming glucose and prepared insulin secretion accordingly.

GIP was identified first, in the early 1970s. GLP-1 was characterized about a decade later. Together they account for the majority of the incretin effect — the amplification of insulin secretion that happens when glucose is absorbed through the digestive tract. In healthy humans, incretins contribute roughly 50–70% of total postprandial insulin secretion. In type 2 diabetes, this incretin effect is dramatically reduced, which is part of why diabetics struggle to control blood glucose after meals.

Glucagon, the third receptor in this story, is not an incretin. It's the metabolic counter-hormone to insulin — released by pancreatic α-cells when blood glucose is low, telling the liver to produce glucose. Its inclusion in modern triple agonists is one of the more counterintuitive developments in metabolic pharmacology, and it took researchers decades to figure out why combining it with GLP-1 would actually help rather than hurt.

GLP-1 Agonism: The Foundation of Modern Metabolic Pharmacology

GLP-1 (glucagon-like peptide-1) is a 30-amino-acid peptide released by L-cells in the small intestine in response to food intake. It binds the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed primarily on pancreatic β-cells, in the brain (especially the hypothalamus and brainstem), and in the gastrointestinal tract.

GLP-1 receptor activation produces four well-characterized effects:

Glucose-dependent insulin secretion. GLP-1 stimulates β-cells to release insulin, but only when blood glucose is elevated. This glucose-dependence is critical — it means GLP-1 agonists don't cause hypoglycemia the way insulin or sulfonylureas can. When glucose is normal, GLP-1 activation does little to insulin release.

Glucagon suppression. GLP-1 simultaneously inhibits glucagon secretion from pancreatic α-cells, which reduces hepatic glucose output. This dual action — boosting insulin while suppressing glucagon — is part of why GLP-1 agonism produces such reliable glycemic improvements.

Slowed gastric emptying. GLP-1 receptors in the gut and brain slow how quickly food moves out of the stomach. This blunts postprandial glucose spikes and extends the sensation of fullness.

Central appetite reduction. GLP-1R activation in the hypothalamus and brainstem reduces food intake. This central effect is the dominant driver of the substantial weight loss seen with high-dose GLP-1 agonists — gastric emptying alone produces only modest weight effects.

The clinical track: GLP-1 agonist drugs have produced some of the largest pharmaceutical successes of the past decade. Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for obesity) is a long-acting GLP-1 analog with an attached fatty acid that extends half-life through albumin binding. Liraglutide (Victoza, Saxenda) is a shorter-acting predecessor. Both produced clinically meaningful weight loss in Phase 3 trials, transforming the treatment landscape for obesity and type 2 diabetes.

Why GLP-1 alone isn't enough: Despite its successes, GLP-1 monotherapy has limits. Maximum weight loss with semaglutide plateaus around 15% of body weight in clinical trials. Many patients respond inadequately. Some develop tolerance to gastric emptying effects. And GLP-1 doesn't directly address adipose tissue biology or hepatic lipid handling. These limitations are part of why researchers started combining GLP-1 with other mechanisms.

GIP Agonism: The Underdog Receptor With a Complicated Past

GIP (glucose-dependent insulinotropic polypeptide) was discovered first among the incretins but became the underdog receptor in metabolic pharmacology for decades. The reason is a paradox: in type 2 diabetes, the insulin-amplifying effect of GIP is dramatically blunted compared to GLP-1's. Early pharmacologists concluded that GIP agonism wouldn't be useful as a therapeutic target — the receptor's effect was already broken in the patients who needed help most.

The conclusion turned out to be wrong, but it took 30 years to figure out why.

GIP is a 42-amino-acid peptide released by K-cells in the duodenum in response to food intake — especially fat and glucose. It binds the GIP receptor (GIPR), expressed on pancreatic β-cells, adipocytes, brain regions involved in food intake regulation, and bone tissue. GIP activates four mechanisms:

Pancreatic insulin secretion. Like GLP-1, GIP stimulates glucose-dependent insulin release from β-cells. In healthy humans, GIP is actually the dominant incretin — contributing more to total incretin effect than GLP-1. In type 2 diabetes, this effect is impaired but not absent.

Glucagon stimulation. Unlike GLP-1, GIP also stimulates glucagon secretion from pancreatic α-cells — at least at low glucose levels. This bidirectional effect on glucagon (raising it during fasting, having less effect during hyperglycemia) is part of GIP's complexity.

Adipose tissue effects. GIP receptors on adipocytes promote fatty acid storage and adipocyte differentiation. Historically, this made GIP agonism look counterproductive for obesity — why would you want to promote fat storage?

Central satiety effects. This is the mechanism that surprised researchers. GIPR signaling in the brain, particularly in hypothalamic and brainstem circuits, reduces food intake. The central satiety effect of GIP agonism turns out to be substantial and may explain much of the benefit of combining GIP with GLP-1.

The paradigm shift: When researchers at Eli Lilly developed tirzepatide — a dual GLP-1/GIP agonist — the assumption was that GIP would be a minor contributor. The Phase 3 SURPASS and SURMOUNT trials revealed something different. Tirzepatide produced substantially more weight loss than semaglutide at comparable GLP-1 receptor occupancy, and the difference was attributable to GIP agonism. Several mechanisms appear to contribute: enhanced central satiety effects, complementary effects on pancreatic insulin secretion, and modulation of adipose tissue insulin sensitivity that may actually reduce fat storage despite GIP's classical lipogenic profile.

The current understanding: GIP agonism amplifies GLP-1's metabolic effects rather than competing with them. The receptor's classical "adipogenic" profile turns out to be more nuanced — chronic GIP receptor activation appears to reduce ectopic fat accumulation and improve insulin sensitivity even while promoting adipocyte differentiation. The complexity is still being characterized in research, but GIP has moved from underdog to essential.

Glucagon Receptor Agonism: The Counterintuitive Third Receptor

Adding a glucagon receptor agonist to a GLP-1/GIP compound sounds, at first, like a contradiction. Glucagon's job is to raise blood glucose — exactly what diabetes therapy is trying to lower. For decades, this made the glucagon receptor look like the wrong target for metabolic drugs. The puzzle was: how do you get the metabolic benefits of glucagon receptor activation without breaking glycemic control?

The answer turned out to be balance. When glucagon receptor agonism is combined with sufficient GLP-1 receptor agonism, the GLP-1-driven insulin secretion offsets glucagon-driven hepatic glucose output. What remains are glucagon's other effects, which are surprisingly useful.

Glucagon is a 29-amino-acid peptide released by pancreatic α-cells in response to low blood glucose. Its receptor, the glucagon receptor (GcgR), is expressed primarily on hepatocytes and adipose tissue, with smaller populations in the heart and kidneys. Glucagon receptor activation produces:

Hepatic glucose output. The classical effect — glycogenolysis and gluconeogenesis in the liver, raising blood glucose. This is what makes glucagon useful for treating hypoglycemia and what made it look unsuitable for diabetes therapy.

Lipolysis in adipose tissue. Glucagon receptors on adipocytes activate hormone-sensitive lipase, mobilizing stored triglycerides for energy use. This is a direct fat-mobilizing effect that GLP-1 doesn't produce.

Increased energy expenditure. Glucagon raises resting metabolic rate, possibly through effects on brown adipose tissue thermogenesis and hepatic substrate cycling. This is the effect that makes glucagon agonism appealing for weight management research despite the glucose-raising effect.

Hepatic lipid mobilization. Glucagon receptor signaling reduces hepatic triglyceride content and is being actively studied in NAFLD and MASH research models. This effect is particularly relevant for research designs investigating fatty liver disease alongside obesity.

Why glucagon agonism works in triple combination: Three things have to be true simultaneously. The GLP-1 agonist component has to produce enough insulin secretion to offset glucagon's hepatic glucose output. The dosing has to be balanced so glucagon receptor activation doesn't dominate. And the glucagon receptor activity needs to be calibrated to capture metabolic benefits (lipolysis, energy expenditure, hepatic lipid mobilization) without overshooting into hyperglycemia.

Retatrutide is the compound that demonstrated this balance is achievable. Its Phase 2 trials showed substantial weight loss (~24% at the highest dose, exceeding tirzepatide) while maintaining glycemic control. The glucagon receptor activity contributes meaningfully to the magnitude of effect — particularly to hepatic lipid mobilization and energy expenditure — that single and dual agonists cannot achieve.

Why Combine Them? The Progression from Single to Triple Agonist

The progression from single to dual to triple receptor agonism represents one of the clearest examples of mechanism-based drug design in recent metabolic pharmacology. Each step adds biology that the previous step cannot reach.

Single agonist (GLP-1 only): Semaglutide and liraglutide. Strong glycemic control through insulin secretion and glucagon suppression. Substantial appetite reduction through central GLP-1 receptor signaling. Modest gastric emptying effects. Limited direct effects on adipose tissue biology or energy expenditure. Maximum weight loss plateaus around 15% of body weight.

Dual agonist (GLP-1 + GIP): Tirzepatide. Adds GIP-mediated amplification of insulin secretion and central satiety. Enhanced weight loss compared to GLP-1 alone (around 22% at highest doses in SURMOUNT trials). Adipose tissue effects begin to emerge through GIP's complex receptor signaling. Still primarily incretin-axis pharmacology.

Triple agonist (GLP-1 + GIP + glucagon): Retatrutide. Adds glucagon-mediated hepatic lipid mobilization, lipolysis, and energy expenditure. Engages metabolic biology beyond the incretin axis. Phase 2 trials reported approximately 24% weight loss at 48 weeks for the highest dose — extending the curve further. The addition of glucagon receptor activity also opens specific research applications in NAFLD/MASH, hepatic lipid biology, and cardiometabolic risk research that single and dual agonists don't address as directly.

The pattern is additive but not linear. Each receptor adds a distinct biological dimension, and the combinations multiply rather than simply sum. A research design probing maximum metabolic effect chooses the triple agonist; a design probing GLP-1-specific pharmacology chooses semaglutide as the reference compound; a design comparing receptor combinations uses all three classes as mechanistic controls.

For research labs working through which compound matches a specific research design, the Best Peptides for Weight Loss Comparison Guide covers compound-by-compound selection criteria across the metabolic peptide category.

The Clinical Landscape: From Ozempic to Retatrutide

The pharmaceutical progression mirrors the pharmacological progression. Understanding the clinical timeline helps contextualize why each compound matters in research.

Late 1990s–2005: Exenatide (Byetta), the first GLP-1 receptor agonist approved for type 2 diabetes, derived from the saliva of the Gila monster lizard. Twice-daily injection. Modest weight loss as a side effect of glycemic improvement.

2010–2014: Liraglutide (Victoza for diabetes, Saxenda for obesity). Once-daily injection. The first GLP-1 agonist approved specifically for chronic weight management.

2017–2021: Semaglutide (Ozempic for diabetes, Wegovy for obesity). Once-weekly injection. Phase 3 STEP trials demonstrated approximately 15% body weight loss — the first time a non-surgical intervention approached bariatric-level weight reduction. Semaglutide became one of the highest-selling drugs in pharmaceutical history.

2022: Tirzepatide (Mounjaro for diabetes, Zepbound for obesity). The first dual GLP-1/GIP agonist. SURMOUNT trials demonstrated approximately 22% body weight loss, exceeding semaglutide and confirming the GIP hypothesis.

2022–present: Retatrutide (LY3437943). The first triple GLP-1/GIP/glucagon agonist to reach advanced clinical development. Phase 2 trials reported approximately 24% body weight loss at 48 weeks. Phase 3 development continues under Eli Lilly's TRIUMPH program. The compound is currently the focus of intense interest among researchers studying maximum-effect metabolic pharmacology.

Other triple agonists are in earlier development at multiple pharmaceutical companies, and additional receptor combinations (amylin, glucagon/GLP-1 dual agonists, peptide-conjugate compounds) are also being explored. The pharmacological space is expanding rapidly.

Research Peptide vs Approved Pharmaceutical: An Important Distinction

The pharmacological mechanisms discussed in this post are the same whether the compound is a research peptide or an approved pharmaceutical. The molecular biology of GLP-1 receptor activation doesn't change based on whether the compound is sold through a pharmacy or a research supplier. However, the compounds themselves are not interchangeable, and the distinction matters for several reasons.

Regulatory status. Approved pharmaceuticals — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) — have been through full clinical development, FDA review, and approval for specific human indications. Research peptides like retatrutide are sold for laboratory use only and are not approved for human consumption through research supplier channels. Retatrutide is in late-stage clinical development but has not yet received regulatory approval.

Manufacturing and quality standards. Approved pharmaceuticals are manufactured under GMP (Good Manufacturing Practice) standards with extensive quality control documentation aimed at human therapeutic use. Research peptides are manufactured under standards appropriate for laboratory research — ≥99% HPLC purity, MS-verified identity, batch-specific COAs. These are different quality frameworks for different purposes, and research peptides should not substitute for approved pharmaceuticals in clinical contexts.

Research utility. Research peptides give laboratories tools to investigate the mechanisms underlying approved drugs. A research lab studying triple agonist pharmacology in animal models works with retatrutide as a research compound, not with Mounjaro or Wegovy. Research peptide sourcing is built for laboratory needs — purity confirmation, batch traceability, supply reliability — not clinical dispensing.

For research labs specifically, sourcing reliability matters as much as compound selection. Cold-chain integrity, batch documentation, and Canadian supply considerations are covered in detail in Research Peptide Storage and Stability for Lab Use.

For research designs that extend beyond receptor-level pharmacology into cellular bioenergetics, the post How Do Mitochondrial Peptides Affect Metabolism? covers compounds like MOTS-c and SS-31 that operate inside cells rather than at receptor surfaces — a complementary mechanism to the incretin and glucagon pharmacology discussed in this post.

Frequently Asked Questions

What is the difference between GLP-1 vs GIP vs glucagon agonism?

GLP-1 agonism stimulates pancreatic insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system effects. GIP agonism amplifies insulin secretion, modulates adipose tissue, and produces central satiety effects that complement GLP-1. Glucagon receptor agonism increases hepatic glucose output, lipolysis, energy expenditure, and hepatic lipid mobilization. Each receptor addresses a different aspect of metabolic biology, and combining them produces effects that no single mechanism achieves alone.

Why is retatrutide considered a triple agonist?

Retatrutide is the first research peptide in advanced clinical development that simultaneously activates the GLP-1, GIP, and glucagon receptors with balanced agonist activity at all three. The structural features that enable this triple agonism include Aib substitutions at DPP-4-vulnerable positions and a C20 fatty diacid acylation that extends circulation time through albumin binding. The triple agonism produces substantially greater body weight reduction in clinical trials than single or dual agonist compounds.

Is tirzepatide an incretin receptor agonist?

Yes. Tirzepatide is a dual incretin receptor agonist — it activates both GLP-1 and GIP receptors. Both GLP-1 and GIP belong to the incretin hormone class, defined by their role in amplifying insulin secretion in response to food intake. Tirzepatide does not engage the glucagon receptor, distinguishing it from the triple agonist class represented by retatrutide.

How does glucagon receptor agonism not cause hyperglycemia in triple agonist?

The balance comes from sufficient GLP-1 receptor agonism in the same compound. GLP-1-driven insulin secretion offsets glucagon's hepatic glucose output, allowing the other glucagon receptor effects (lipolysis, energy expenditure, hepatic lipid mobilization) to contribute to overall metabolic improvement without compromising glycemic control. This balance is the central pharmacological achievement of compounds like retatrutide and is one of the reasons triple agonism took decades to engineer successfully.

What are the next-generation peptides beyond triple agonists?

Multiple development programs are exploring additional receptor combinations and conjugate compounds. Amylin receptor agonists (cagrilintide) are being combined with GLP-1 agonists. Long-acting glucagon/GLP-1 dual agonists are in development. Peptide-conjugate compounds combining incretin pharmacology with other classes (FGF21, GDF15) are being characterized. The pharmacological space is expanding rapidly, and triple agonists are not the final word in metabolic peptide design.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.